Risedronate sodium monohydrate is a third-generation pyridinyl bisphosphonate used as a potent antiresorptive agent to inhibit osteoclast-mediated bone resorption. It is mainly utilized in the management of skeletal disorders characterized by increased bone turnover, including osteoporosis and Paget’s disease. It is grouped under the following drug class(es): Bisphosphonates. Its therapeutic use is listed as anti-osteoporosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Risedronate sodium hydrate and Risedronic acid monosodium salt monohydrate. Its PubChem CID is 23709605.
Risedronate sodium monohydrate
| CAS No | 353228-19-0 |
|---|---|
| Molecular Formula | C7H12NNaO8P2 |
| Molecular Weight | 323.11 g/mol |
| Synonyms | sodium;hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Risedronate sodium monohydrate is a third-generation pyridinyl bisphosphonate used as a potent antiresorptive agent to inhibit osteoclast-mediated bone resorption.
The listed CAS number is 353228-19-0.
The listed molecular formula is C7H12NNaO8P2.
The listed molecular weight is 323.11 g/mol.
sodium;hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate;hydrate.
The source lists Risedronate sodium hydrate and Risedronic acid monosodium salt monohydrate.